COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.
COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.
复制标题
肌无力重症患者的COVID-19疫苗接种：单中心病例系列。
DOI：
10.3390/vaccines9101112
复制
发表时间：
2021-09-29
期刊：
影响因子：
7.8
通讯作者：
Chang T
中科院分区：
文献类型：
--
作者：
Ruan Z;Tang Y;Li C;Sun C;Zhu Y;Li Z;Chang T
在这项研究中，我们报告了2019冠状病毒病（COVID-19）疫苗在重症肌无力（MG）患者中的安全性。包括接种COVID-19疫苗的患者。收集人口统计学、临床特征、药物和疫苗接种信息。主要观察结果为接种COVID-19疫苗后4周内MG症状恶化。共纳入22名接种COVID-19疫苗的MG患者。10例（45.5%）患者为眼部MG（OMG），12例（55.5%）患者为全身MG（GMG）。6例（27.3%）患者为女性，平均（SD）发病年龄为45.4（11.8）岁。19例（86.4%）患者血清乙酰胆碱受体（AChR）抗体阳性。7例（31.8%）患者行胸腺切除术，其中4例经病理证实为胸腺瘤。21例患者接种灭活疫苗，1例患者接种重组亚单位疫苗。20名（90.9%）患者在COVID-19疫苗接种后4周内未出现MG症状恶化，2名（9.1%）患者报告轻微症状恶化，但在几天内迅速消退。我们的研究结果表明，灭活COVID-19疫苗在美国重症肌无力基金会（MGFA）I至II级的MG患者中可能是安全的，支持在仍在扩大的COVID-19大流行期间促进MG患者接种疫苗的建议。
In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.
登录
查看更多内容
DOI：
10.7759/cureus.15581
发表时间：
2021-06
期刊：
Cureus
影响因子：
--
作者：
Tagliaferri AR;Narvaneni S;Azzam MH;Grist W
通讯作者：
Grist W
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.3988/jcn.2017.13.4.325
发表时间：
2017-10
期刊：
Journal of clinical neurology (Seoul, Korea)
影响因子：
--
作者：
Seok HY;Shin HY;Kim JK;Kim BJ;Oh J;Suh BC;Kim SY;Kang SY;Ahn SW;Bae JS;Kim BJ
通讯作者：
Kim BJ
影响因子：
9.9
作者：
Sole, Guilhem;Mathis, Stephane;Attarian, Shahram
通讯作者：
Attarian, Shahram
影响因子：
158.5
作者：
Keech, Cheryl;Albert, Gary;Glenn, Gregory M.
通讯作者：
Glenn, Gregory M.